摘要
目的探讨达格列净治疗老年射血分数保留心力衰竭合并2型糖尿病患者的临床效果。方法回顾性分析2020年9月至2021年3月中国科学技术大学附属第一医院(安徽省立医院)全科医学科住院的82例老年射血分数保留的心力衰竭合并2型糖尿病患者病历资料,根据用药方案分为对照组41例,达格列净组41例。2组均采用常规降糖药物及抗心力衰竭药物治疗,达格列净组加用达格列净10 mg/d,观察3个月。随访患者治疗前、治疗3个月后心功能指标血浆N末端B型利钠肽原(NT-proBNP)、患者6 min步行距离及再入院率。超声心动图参数包括:左心室舒张早期左房室瓣血流最大速度(E)/舒张早期左房室瓣环峰值速度(e′)、左心房容积指数(LAVI)、左心室射血分数(LVEF)等。结果与对照组比较,达格列净组治疗3个月后LAVI、E/e′、C反应蛋白、NT-proBNP水平明显降低(P<0.05)。达格列净组的6 min步行距离及LVEF较对照组明显提高(P<0.05)。达格列净组和对照组随访3个月因心力衰竭再次住院患者分别为6例(14.6%)、14例(34.1%),差异有统计学意义(P=0.04)。结论达格列净在老年射血分数保留心力衰竭合并2型糖尿病患者的治疗中能够改善患者的心力衰竭症状,降低再入院率。
Objective To analyze the clinical efficicy of dapagliflozin in elderly HFpEF patients with type 2 diabetes.Methods Eighty-two elderly HFpEF patients with type 2 diabetes were divided into control group(n=41)and dapagliflozin treatment group(n=41),The all patients were received conventional medical treatment according to the blood glucose level and the NYHA classification.The drug group was combined with Dapag(10 mg/d),The echocardiography parameters(E/e′,LAVI,and LVEF),NT-proBNPand readmission rate were recorded before treatment and after 3 months of treatment.Results As compared with the control group,the patients in the dapagliflozin group had a significant decreased serum NT-proBNP,CRP,LAVI,E/e′(P<0.05),6MWT and LVEF were significantly improved in the dapagliflozin group.The patients in two groups were followed up for 3 months,during which 6 patients(14.6%)in dagliflozin treatment group and 14 patients(34.1%)in control group were readmitted due to HF.Conclusions Dapagliflozin can improve the cardiac function in elderly HFpEF patients with type 2DM and reduce readmission rate.
作者
宋青青
范西真
付伟
崔东岳
王娟
王喆
Song Qingqing;Fan Xizhen;Fu Wei;Cui Dongyue;Wang Juan;Wang Zhe(Department of General Medicine,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China)
出处
《中国临床保健杂志》
CAS
2022年第3期359-362,共4页
Chinese Journal of Clinical Healthcare
基金
安徽省重点研究与开发项目(1704f0804014)。